BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18031189)

  • 1. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.
    Bardsley-Elliot A; Noble S; Foster RH
    BioDrugs; 1999 Nov; 12(5):363-410. PubMed ID: 18031189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.
    Young M; Plosker GL
    Pharmacoeconomics; 2002; 20(10):675-713. PubMed ID: 12162756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection.
    Sanford M; Keating GM
    Drugs; 2008; 68(17):2505-33. PubMed ID: 19016576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil: a unique immunosuppressive agent.
    Hood KA; Zarembski DG
    Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of mycophenolate mofetil in kidney transplantation].
    Hrvacevic R; Ignjatovic Lj; Vavic N
    Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients.
    Ensley RD; Bristow MR; Olsen SL; Taylor DO; Hammond EH; O'Connell JB; Dunn D; Osburn L; Jones KW; Kauffman RS
    Transplantation; 1993 Jul; 56(1):75-82. PubMed ID: 8333071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.
    Ross DJ; Waters PF; Levine M; Kramer M; Ruzevich S; Kass RM
    J Heart Lung Transplant; 1998 Aug; 17(8):768-74. PubMed ID: 9730425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycophenolate mofetil--a new immunosuppressive agent].
    Bergan S; Albrechtsen D; Fauchald P
    Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2439-41. PubMed ID: 8928103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.